ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ASCO 2024 abstract movers – Merus convinces, at first
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
Verastem spoils its ASCO bounce
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
